B cells are recognized as main actors in the autoimmune process. Autoreactive B cells can arise in the bone marrow or in the periphery and, if not properly inhibited or eliminated, can lead to autoimmune diseases through several mechanisms: autoantibody production and immune complex formation, cytokine and chemokine synthesis, antigen presentation, T cell activation, and ectopic lymphogenesis. The availability of agents capable of depleting B cells (that is, anti-CD20 and anti-CD22 monoclonal antibodies) or targeting B cell survival factors (atacicept and belimumab) opens new perspectives in the treatment of diseases such as systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes, and multiple sclerosis.
B cell-targeted therapies in autoimmunity: rationale and progress / P. Fiorina, M.H. Sayegh. - In: F1000 BIOLOGY REPORTS. - ISSN 1757-594X. - 1(2009 May 28), pp. 39.1-39.4.
|Titolo:||B cell-targeted therapies in autoimmunity: rationale and progress|
FIORINA, PAOLO (Primo)
|Settore Scientifico Disciplinare:||Settore MED/13 - Endocrinologia|
|Data di pubblicazione:||28-mag-2009|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.3410/B1-39|
|Appare nelle tipologie:||01 - Articolo su periodico|